公开(公告)号：US10266532B2

公开(公告)日：2019-04-23

申请号：US15829243

申请日：2017-12-01

Applicant: AbbVie Inc.

Inventor： Eric C. Breinlinger ,  Phil B. Cox ,  Justin D. Dietrich ,  Kristine E. Frank ,  Michael M. Friedman ,  Huan-Qui Li ,  Kenton L. Longenecker ,  Augustine T. Osuma ,  Ann Marie Rowley ,  Anil Vasudevan ,  Noel S. Wilson ,  Jerome Daanen ,  Stevan Djuric ,  Amanda W. Dombrowski ,  Arthur Gomtsyan ,  Robert Schmidt

IPC: C07D521/00 ,  C07D471/04 ,  C07D471/14 ,  C07D487/04 ,  C07D498/04 ,  C07D498/14 ,  C07D498/18 ,  C07D498/20 ,  C07D498/22 ,  C07D519/00 ,  C07D471/18 ,  C07D491/147 ,  C07D491/22

Abstract: The invention provides tricyclic heterocyclic compounds, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the invention may be useful for treating immunological and oncological conditions.

公开(公告)号：US20180179198A1

公开(公告)日：2018-06-28

申请号：US15829243

申请日：2017-12-01

Applicant: AbbVie Inc.

Inventor： Eric C. Breinlinger ,  Phil B. Cox ,  Justin D. Dietrich ,  Kristine E. Frank ,  Michael M. Friedman ,  Huan-Qui Li ,  Kenton L. Longenecker ,  Augustine T. Osuma ,  Ann Marie Rowley ,  Anil Vasudevan ,  Noel S. Wilson

IPC: C07D471/04 ,  C07D491/147 ,  C07D498/22 ,  C07D487/04 ,  C07D491/22 ,  C07D498/18 ,  C07D471/14 ,  C07D498/04 ,  C07D498/14 ,  C07D498/20 ,  C07D519/00 ,  C07D471/18

CPC classification number: C07D471/04 ,  C07D471/14 ,  C07D471/18 ,  C07D487/04 ,  C07D491/147 ,  C07D491/22 ,  C07D498/04 ,  C07D498/14 ,  C07D498/18 ,  C07D498/20 ,  C07D498/22 ,  C07D519/00

Abstract: The invention provides tricyclic heterocyclic compounds, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the invention may be useful for treating immunological and oncological conditions.

公开(公告)号：US20170320880A1

公开(公告)日：2017-11-09

申请号：US15588398

申请日：2017-05-05

Applicant: AbbVie Inc.

Inventor： Michael R. Michaelides ,  Michael L. Curtin ,  Huan-Qiu Li ,  Marina A. Pliushchev ,  Ying Wang ,  Hongyu H. Zhao ,  Richard F. Clark ,  Alan S. Florjancic ,  Zhiqin Ji ,  Mariazel Torrent ,  Ramzi F. Sweis ,  Anil Vasudevan ,  Justin D. Dietrich

IPC: C07D487/04 ,  C07D417/14 ,  C07D413/10 ,  C07D405/04 ,  C07D403/14 ,  C07D403/12 ,  C07D403/10 ,  C07D403/04 ,  C07D401/14 ,  C07D401/12 ,  C07D401/04 ,  C07D471/04 ,  C07D207/14

CPC classification number: C07D487/04 ,  A61K31/40 ,  C07D207/14 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/10 ,  C07D403/12 ,  C07D403/14 ,  C07D405/04 ,  C07D413/10 ,  C07D417/14 ,  C07D471/04

Abstract: Compounds having a structure of Formula (I): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein A1, A2, A3, A4, A5, n, and m are as defined herein and are provided. Pharmaceutical compositions comprising such compounds and methods for treating various EED-related conditions or diseases, including cancer, by administration of such compounds are also provided.

公开(公告)号：US20240158368A1

公开(公告)日：2024-05-16

申请号：US18379351

申请日：2023-10-12

Applicant: AbbVie Inc.

Inventor： David A. Degoey ,  Michael R. Schrimpf ,  David J. Hardee ,  Jacob Ludwig ,  Eric R. Miller ,  Timothy R. Hodges ,  Alberto Munoz ,  Sarah J. Perlmutter ,  Huan-Qiu X. Li ,  Alvin Jang ,  Elizabeth L. Noey ,  Gregory A. Gfesser ,  Edgars Jecs ,  Robert G. Schmidt ,  Justin D. Dietrich ,  Xenia B. Searle ,  Boguslaw P. Nocek ,  Andrew Bogdan

IPC: C07D401/12 ,  A61P31/14

CPC classification number: C07D401/12 ,  A61P31/14

Abstract: Pyrrolidine main protease inhibitors are described that are effective as antiviral compounds.

公开(公告)号：US11312668B2

公开(公告)日：2022-04-26

申请号：US17060801

申请日：2020-10-01

Applicant: AbbVie Deutschland GmbH & Co. KG ,  AbbVie Inc.

Inventor： Wilfried Braje ,  Katarina Britze ,  Justin D. Dietrich ,  Anais Jolit ,  Johannes Kaschel ,  Johanna Klee ,  Tanja Lindner

IPC: C07D213/74 ,  C07D215/227 ,  C07D239/26 ,  C07D239/42 ,  C07D307/36 ,  C07D307/81 ,  C07D311/58 ,  C07D405/04 ,  C07D409/04 ,  C07D471/04 ,  C07D495/04 ,  C07B63/04 ,  C07B43/06 ,  C07F5/02 ,  C07B43/04 ,  C07B37/04 ,  C07C41/46 ,  C07C67/62 ,  C07C209/90 ,  C07C213/10 ,  C07C231/22 ,  C07C253/32 ,  C07C269/08 ,  C07C273/18 ,  C07C303/42 ,  C07C319/26 ,  C07D205/04 ,  C07D207/34 ,  C07D209/08 ,  C07D209/48 ,  C07D211/06

Abstract: The present invention relates to a method of carrying out an organic reaction in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose.

公开(公告)号：US10035800B2

公开(公告)日：2018-07-31

申请号：US14774866

申请日：2014-03-12

Applicant: AbbVie Inc.

Inventor： Steven D. Fidanze ,  Dauchun Liu ,  Robert A. Mantei ,  Keith F. McDaniel ,  John Pratt ,  George S. Sheppard ,  Le Wang ,  Andrew Bogdan ,  James H. Holms ,  Justin D. Dietrich ,  Jasmina Marjanovic ,  Lisa A. Hasvold ,  Yujia Dai

IPC: A61K31/437 ,  C07D471/22 ,  C07D471/16

CPC classification number: C07D471/22 ,  A61P13/12 ,  A61P15/16 ,  A61P31/18 ,  A61P35/00 ,  C07D471/16

Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R6, Y1, Y3, A1, A2, A3 and A4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).

公开(公告)号：US20200291027A1

公开(公告)日：2020-09-17

申请号：US16827026

申请日：2020-03-23

Applicant: AbbVie Inc.

Inventor： Steven D. Fidanze ,  Dachun Liu ,  Robert A. Mantei ,  Keith F. McDaniel ,  John Pratt ,  George S. Sheppard ,  Le Wang ,  Andrew Bogdan ,  James H. Holms ,  Justin D. Dietrich ,  Jasmina Marjanovic ,  Lisa A. Hasvold ,  Yujia Dai

IPC: C07D471/22 ,  A61P15/16 ,  A61P31/18 ,  A61P13/12 ,  A61P35/00 ,  C07D471/16

Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R6, Y1, Y2, Y3, A1, A2, A3, and A4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).

公开(公告)号：US10160748B2

公开(公告)日：2018-12-25

申请号：US15670708

申请日：2017-08-07

Applicant: AbbVie Inc.

Inventor： Maria Argiriadi ,  Eric Breinlinger ,  Justin D. Dietrich ,  Michael Friedman ,  David Ihle ,  Michael Morytko ,  Kelly Mullen ,  Augustine Osuma ,  Gloria Y. LoSchiavo ,  Noel S. Wilson

IPC: C07D403/04 ,  C07F9/6558 ,  C07D413/04 ,  C07D471/04 ,  C07D405/04 ,  C07D491/107 ,  C07D487/04 ,  C07D401/14 ,  C07D417/04 ,  C07D403/14 ,  C07D498/04 ,  C07D401/04 ,  C07D413/14 ,  C07D405/14 ,  C07D417/14

Abstract: The disclosure provides indazolone compounds, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the disclosure may be useful for treating immunological and oncological conditions.

公开(公告)号：US20160304496A1

公开(公告)日：2016-10-20

申请号：US15130279

申请日：2016-04-15

Applicant: AbbVie Inc.

Inventor： Maria Argiriadi ,  Eric Breinlinger ,  Justin D. Dietrich ,  Michael Friedman ,  David Ihle ,  Michael Morytko ,  Kelly Mullen ,  Augustine Osuma ,  Glora Y. Lo Schiavo ,  Noel S. Wilson

IPC: C07D403/04 ,  C07D403/14 ,  C07D491/107 ,  C07D405/14 ,  C07D487/04 ,  C07D405/04 ,  C07D417/14 ,  C07D401/04 ,  C07D417/04 ,  C07D413/04 ,  C07D471/04 ,  C07F9/6558 ,  C07D401/14 ,  C07D498/04

CPC classification number: C07D403/04 ,  C07D401/04 ,  C07D401/14 ,  C07D403/14 ,  C07D405/04 ,  C07D405/14 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  C07D491/107 ,  C07D498/04 ,  C07F9/65583

Abstract: The disclosure provides indazolone compounds, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the disclosure may be useful for treating immunological and oncological conditions.

Abstract translation: 本公开提供吲哚酮化合物，药学上可接受的盐，前药，生物活性代谢物，立体异构体和异构体，其中变量在本文中定义。 本公开的化合物可用于治疗免疫学和肿瘤学病症。

公开(公告)号：US20180298003A1

公开(公告)日：2018-10-18

申请号：US16018357

申请日：2018-06-26

Applicant: AbbVie Inc.

Inventor： Steven D. Fidanze ,  Dachun Liu ,  Robert A. Mantei ,  Keith F. McDaniel ,  John Pratt ,  George S. Sheppard ,  Le Wang ,  Andrew Bogdan ,  James H. Holms ,  Justin D. Dietrich ,  Jasmina Marjanovic ,  Lisa A. Hasvold ,  Yujia Dai

IPC: C07D471/22 ,  C07D471/16

Abstract: The present invention provides for compounds of formula (I) wherein R1, R2, R6, Y1, Y2, Y3, A1, A2, A3, and A4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).